Open AccessP95Effects of dabrafenib and trametinib, cancer therapies that target BRaf and MEK, on cardiac signalling
Author(s) -
Angela Clerk,
Luke Connell,
Michelle Pipe,
SJ Fuller,
PH Sugden
Publication year - 2014
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1093/cvr/cvu082.37
Subject(s) - trametinib , dabrafenib , mapk/erk pathway , cancer research , mek inhibitor , kinase , protein kinase b , medicine , phosphorylation , cancer , pi3k/akt/mtor pathway , melanoma , biology , vemurafenib , signal transduction , endocrinology , microbiology and biotechnology , metastatic melanoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom